<?xml version="1.0" ?>
<tei xml:space="preserve">
	<teiHeader>
		<fileDesc xml:id="-1"/>
	</teiHeader>
	<text xml:lang="en">
			<front>Decoding the historical tale: COVID-19 impact on <lb/>haematological malignancy patients-EPICOVIDEHA insights <lb/>from 2020 to 2022 <lb/>Jon Salmanton-García, a,b,c,eg, * * Francesco Marchesi, d,eg Francesca Farina, e Barbora Weinbergerová, f Federico Itri, g Julio Dávila-Valls, h Sonia Martín-<lb/>Pérez, h Andreas Glenthøj, i Ditte Stampe Hersby, i Maria Gomes Da Silva, j Raquel Nunes Rodrigues, j Alberto López-García, k Raúl Córdoba, k <lb/>Yavuz M. Bilgin, l Iker Falces-Romero, m,n Shaimaa El-Ashwah, o Ziad Emarah, o,p Caroline Besson, q Milena Kohn, q Jaap Van Doesum, r <lb/>Emanuele Ammatuna, r Monia Marchetti, s Jorge Labrador, t Giovanni Paolo Maria Zambrotta, u,v Luisa Verga, u,v Ozren Jaksic, w Marcio Nucci, x <lb/>Klára Piukovics, y Alba Cabirta-Touzón, z Moraima Jiménez, z Elena Arellano, aa Ildefonso Espigado, aa Ola Blennow, ab Anna Nordlander, ab Stef Meers, ac <lb/>Jens Vian Praet, ad Tommaso Francesco Aiello, ae Carolina Garcia-Vidal, ae Nicola S. Fracchiolla, af Mariarita Sciumè, af Guldane Cengiz Seval, ag <lb/>Pavel Žák, ah Caterina Buquicchio, ai Carlo Tascini, aj Stefanie K. Gräfe, ak Martin Schönlein, al Tatjana Adžić-VUKI ČEVI Ć, am Valentina Bonuomo, an <lb/>Chiara Cattaneo, ao Summiya Nizamuddin, ap Martin Čerňan, aq Gaëtan Plantefeve, ar Romane Prin, as Tomas Szotkovski, aq Graham P. Collins, at <lb/>Michelina Dargenio, au Verena Petzer, av Dominik Wolf, av Natasha Čolović, aw Lucia Prezioso, ax Toni Valković, ay,az,ba Francesco Passamonti, bb Gustavo-<lb/>Adolfo Méndez, bc Uluhan Sili, bd Antonio Vena, be Martina Bavastro, be Alessandro Limongelli, be Rafael F. Duarte, bf Marie-Pierre Ledoux, bg <lb/>Milche Cvetanoski, bh Zlate Stojanoski, bh Marina Machado, bi Josip Batinić, az,bj,bk Gabriele Magliano, bl Monika M. Biernat, bm Nikola Pantić, bn <lb/>Christian Bjørn Poulsen, bo Annarosa Cuccaro, bp,bq Maria Ilaria Del Principe, br Austin Kulasekararaj, bs Irati Ormazabal-Vélez, bt Alessandro Busca, bu <lb/>Fatih Demirkan, bv Marriyam Ijaz, ap Nikolai Klimko, bw Igor Stoma, bx Sofya Khostelidi, bw Noemí Fernández, by Ali S. Omrani, bz Rui Bergantim, ca Nick De <lb/>Jonge, cb Guillemette Fouquet, cc Milan Navrátil, cd Ghaith Abu-Zeinah, ce Michail Samarkos, cf Johan Maertens, cg Cristina De Ramón, ch Anna Guidetti, ci <lb/>Ferenc Magyari, cj Tomás José González-López, ck Tobias Lahmer, cl Olimpia Finizio, cm Natasha Ali, cn László Imre Pinczés, cj Esperanza Lavilla-Rubira, co <lb/>Alessandra Romano, cp Maria Merelli, aj Mario Delia, cq Maria Calbacho, cr Joseph Meletiadis, cs Darko Antić, bn José-Ángel Hernández-Rivas, ct <lb/>Joyce Marques De Almeida, cu Murtadha Al-Khabori, cv Martin Hoenigl, cw,cx Maria Chiara Tisi, cy Nina Khanna, cz Aleksandra Barać, bn Noha Eisa, o,da <lb/>Roberta Di Blasi, db Raphaël Liévin, db Carolina Miranda-Castillo, dc Nathan C. Bahr, dd Sylvain Lamure, de Mario Virgilio Papa, df Ayel Yahya, da <lb/>Avinash Aujayeb, dg Jan Novák, dh Nurettin Erben, di María Fernández-Galán, dj José-María Ribera-Santa Susana, dk Ikhwan Rinaldi, dl Rita Fazzi, dm <lb/>Monica Piedimonte, dn Rémy Duléry, do Yung Gonzaga, dp Andrés Soto-Silva, dq Giuseppe Sapienza, dr Alexandra Serris, ds Ľuboš Drgoňa, dt Ana Groh, du <lb/>Laura Serrano, dv Eleni Gavriilaki, dw Athanasios Tragiannidis, dw Juergen Prattes, cw,cx Nicola Coppola, dx Vladimir Otašević, bn Miloš Mladenović, an <lb/>Mirjana Mitrović, bn Bojana Mišković, dy Pavel Jindra, dz Sofia Zompi, bu Maria Vittoria Sacchi, s Carolin Krekeler, ea Evgenii Shumilov, ea <lb/>Maria Stefania Infante, ct Daniel García-Bordallo, co Gökçe Melis Çolak, bd Antonella Cingolani, eb Jiří Mayer, f Marianna Criscuolo, eb Marietta Nygaard, bo <lb/>Michaela Hanáková, ec Luana Fianchi, eb Zdeněk Ráčil, ec,ed Antonio Giordano, eb Martina Quattrone, eb Matteo Bonanni, eb Philipp Koehler, a,b <lb/>Laman Rahimli, a,b Oliver A. Cornely, a,b,c,ee,eh and Livio Pagano, eb,ef,eh, * on behalf of the EPICOVIDEHA Registry <lb/>a <lb/>University of Cologne, Faculty of Medicine, and University Hospital Cologne, Institute of Translational Research, Cologne Excellence <lb/>Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany <lb/>b <lb/>University of Cologne, Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, Center for Integrated <lb/>Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany <lb/>c <lb/>German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany <lb/>d <lb/>Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy <lb/>e <lb/>IRCCS Ospedale San Raffaele, Milan, Italy <lb/>f <lb/>Masaryk University and University Hospital Brno -Department of Internal Medicine, Hematology and Oncology, Brno, Czech Republic <lb/>g <lb/>San Luigi Gonzaga Hospital -Orbassano, Orbassano, Italy <lb/>h <lb/>Hospital Nuestra Señora de Sonsoles, Ávila, Spain <lb/>i <lb/>Department of Hematology, Copenhagen University Hospital -Rigshospitalet, Copenhagen, Denmark <lb/>j <lb/>Portuguese Institute of Oncology, Lisbon, Portugal <lb/>k <lb/>Fundación Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain <lb/>l <lb/>Department of Internal Medicine, ADRZ, Goes, Netherlands <lb/>m <lb/>Microbiology and Parasitology Department, University Hospital La Paz, Madrid, Spain <lb/>n <lb/>CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain <lb/>o <lb/>Oncology Center, Mansoura University, Mansoura, Egypt <lb/>*Corresponding author. Fondazione Policlinico Universitario A. Gemelli -IRCCS -Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, <lb/>Rome 00168, Italy. <lb/>**Corresponding author. University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence <lb/>Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Herderstrasse 52, Cologne 50931, Germany. <lb/>E-mail addresses: livio.pagano@unicatt.it (L. Pagano), jon.salmanton-garcia@uk-koeln.de (J. Salmanton-García). <lb/>eg <lb/>Shared junior authorship. <lb/>eh <lb/>Shared senior authorship. <lb/>www.thelancet.com Vol 71 May, 2024 <lb/>1 <lb/>Articles <lb/>p <lb/>King Abdullah Medical City, Makkah, Saudi Arabia <lb/>q <lb/>Centre Hospitalier de Versailles, Le Chesnay, France; Université Paris-Saclay, UVSQ, Inserm, Équipe &quot;Exposome et Hérédité&quot;, CESP, <lb/>Villejuif, France <lb/>r <lb/>University Medical Center Groningen, Groningen, Netherlands <lb/>s <lb/>Hematology and Transplant Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy <lb/>t <lb/>Department of Hematology, Research Unit, Hospital Universitario de Burgos, Burgos, Spain <lb/>u <lb/>Azienda Ospedaliera San Gerardo -Monza, Monza, Italy <lb/>v Università Milano-Bicocca, Milan, Italy <lb/>w <lb/>University Hospital Dubrava, Zagreb, Croatia <lb/>x Department of Internal Medicine, Federal University of Rio de Janeiro and Grupo Oncoclinicas, Rio de Janeiro, Brazil <lb/>y <lb/>Department of Internal Medicine, South Division Faculty of Medicine University of Szeged, Szeged, Hungary <lb/>z <lb/>Department of Hematology, Vall d&apos;Hebron Hospital Universitari, Experimental Hematology, Vall d&apos;Hebron Institute of Oncology <lb/>(VHIO), Vall d&apos;Hebron Barcelona Hospital Campus, Barcelona, Spain <lb/>aa <lb/>Department of Hematology, University Hospital Virgen Macarena -University Hospital Virgen del Rocío, Instituto de Biomedicina de <lb/>Sevilla (IBIS / CSIC), Universidad de Sevilla (Departamento de Medicina), Seville, Spain <lb/>ab <lb/>Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden <lb/>ac <lb/>AZ KLINA, Brasschaat, Belgium <lb/>ad <lb/>Department of Nephrology and Infectious diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium <lb/>ae <lb/>Department of Infectious Diseases, Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain <lb/>af <lb/>Hematology Unit, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy <lb/>ag <lb/>Ankara University, Ankara, Turkey <lb/>ah <lb/>University Hospital Hradec Králové, Hradec Králové, Czech Republic <lb/>ai <lb/>Ematologia con Trapianto, Ospedale Dimiccoli Barletta, Barletta, Italy <lb/>aj <lb/>Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy <lb/>ak <lb/>Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany <lb/>al <lb/>Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center <lb/>Hamburg-Eppendorf, Hamburg, Germany <lb/>am <lb/>COVID hospital &quot;Batajnica&quot;, Belgrade, Serbia <lb/>an Policlinico Borgo Roma Verona, Verona, Italy <lb/>ao <lb/>Hematology Unit, ASST-Spedali Civili, Brescia, Italy <lb/>ap <lb/>Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan <lb/>aq <lb/>University Hospital Olomouc, Olomouc, Czech Republic <lb/>ar <lb/>Head ICU and CRC, Centre Hospitalier Victor DUPOUY, Argenteuil, France <lb/>as <lb/>CRA from CRC Centre Hospitalier Victor DUPOUY, Argenteuil, France <lb/>at <lb/>Oxford University Hospitals, Oxford, United Kingdom <lb/>au <lb/>Ospedale Vito Fazzi, Lecce, Italy <lb/>av <lb/>Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck (MUI), <lb/>Innsbruck, Austria <lb/>aw <lb/>University Clinical Center Serbia, Belgrade, Serbia <lb/>ax <lb/>Hospital University of Parma -Hematology and Bone Marrow Unit, Parma, Italy <lb/>ay <lb/>University Hospital Centre Rijeka, Rijeka, Croatia <lb/>az <lb/>Croatian Cooperative Group for Hematological Diseases (CROHEM), Croatia <lb/>ba <lb/>Faculty of Medicine and Faculty of Health Studies of University of Rijeka, Rijeka, Croatia <lb/>bb <lb/>Department of Medicine and Surgery, University of Insubria and ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy <lb/>bc <lb/>Hospital Escuela de Agudos Dr. Ramón Madariaga, Posadas, Argentina <lb/>bd <lb/>Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Turkey <lb/>be <lb/>Ospedale Policlinico San Martino, Genoa, Italy <lb/>bf <lb/>Hospital Universitario Puerta de Hierro, Majadahonda, Spain <lb/>bg <lb/>ICANS, Strasbourg, France <lb/>bh <lb/>University Clinic of Hematology, Skopje, North Macedonia <lb/>bi <lb/>Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain <lb/>bj <lb/>University Hospital Centre Zagreb, Zagreb, Croatia <lb/>bk <lb/>Faculty of Medicine University of Zagreb, Zagreb, Croatia <lb/>bl <lb/>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy <lb/>bm <lb/>Wroclaw Medical University, Wroclaw, Poland <lb/>bn University Clinical Center of Serbia, Belgrade, Serbia <lb/>bo <lb/>Zealand University Hospital, Roskilde, Denmark <lb/>bp <lb/>Hematology Unit, Center for Translational Medicine, Azienda USL Toscana NordOvest, Livorno, Italy <lb/>bq <lb/>National Cancer Institute, Fondazione &apos;G. Pascale&apos;, IRCCS, Hematology-Oncology and Stem Cell Transplantation Unit, Naples, Italy <lb/>Articles <lb/>2 <lb/>www.thelancet.com Vol 71 May, 2024 <lb/>br <lb/>Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy <lb/>bs <lb/>Department of Hematological Medicine, King&apos;s College Hospital NHS Foundation Trust, London, United Kingdom <lb/>bt <lb/>Hospital Universitario de Navarra, Iruña-Pamplona, Spain <lb/>bu <lb/>Stem Cell Transplant Center, AOU Citta&apos; della Salute e della Scienza, Turin, Italy <lb/>bv <lb/>Dokuz Eylul University, Division of Hematology, Izmir, Turkey <lb/>bw <lb/>North-Western State Medical University named after Iliá Ilich Méchnikov, Saint-Petersburg, Russia <lb/>bx <lb/>Gomel State Medical University, Gomel, Belarus <lb/>by <lb/>Hospital Universitario Marqués de Valdecilla, Santander, Spain <lb/>bz <lb/>Hamad Medical Corporation, Doha, Qatar <lb/>ca <lb/>Centro Hospitalar e Universitário São João, Porto, Portugal <lb/>cb <lb/>Amsterdam UMC, location VUmc, Amsterdam, Netherlands <lb/>cc <lb/>Department of Hematology, CH Sud Francilien, Corbeil Essonnes, France <lb/>cd <lb/>University Hospital Ostrava, Ostrava, Czech Republic <lb/>ce <lb/>Weill Cornell Medicine, New York, United States <lb/>cf <lb/>Laikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece <lb/>cg <lb/>KU Leuven, Leuven, Belgium <lb/>ch <lb/>Hospital Universitario de Salamanca, Salamanca, Spain <lb/>ci <lb/>University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy <lb/>cj <lb/>Division of Hematology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary <lb/>ck <lb/>Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain <lb/>cl <lb/>Medizinische Klinik II, Klinikum rechts der Isar, TU München, Munich, Germany <lb/>cm <lb/>UOC Hematology, AORN Cardarelli, Naples, Italy <lb/>cn <lb/>Aga Khan University, Karachi, Pakistan <lb/>co <lb/>Hospital Universitario Lucus Augusti, Lugo, Spain <lb/>cp <lb/>AOU Policlinico Rodolico San Marco, Catania, Italy <lb/>cq <lb/>Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy <lb/>cr <lb/>Hospital Universitario 12 de Octubre, Madrid, Spain <lb/>cs <lb/>Clinical Microbiology Laboratory, Medical School, &quot;Attikon&quot; University General Hospital, National and Kapodistrian University of <lb/>Athens, Athens, Greece <lb/>ct <lb/>Hospital Universitario Infanta Leonor, Madrid, Spain <lb/>cu <lb/>Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland <lb/>cv Sultan Qaboos University Hospital, Muscat, Oman <lb/>cw <lb/>Division of Infectious Diseases, ECMM Excellence Center for Clinical Mycology, Department of Internal Medicine, Medical University of <lb/>Graz, Austria <lb/>cx BioTechMed, Graz, Austria <lb/>cy <lb/>San Bortolo Hospital, Vicenza, Italy <lb/>cz <lb/>University Hospital of Basel, Basel, Switzerland <lb/>da <lb/>Aseer Central Hospital, Abha, Saudi Arabia <lb/>db <lb/>Hopital Saint Louis, Paris, France <lb/>dc <lb/>Hospital Rey Juan Carlos, Móstoles, Spain <lb/>dd <lb/>University of Kansas Medical Center, Kansas City, United States <lb/>de <lb/>Department of Clinical Hematology, Montpellier University Hospital, IGMM UMR5535 CNRS, University of Montpellier, Montpellier, <lb/>France <lb/>df <lb/>Azienda Ospedaliera Sant&apos;Anna e San Sebastiano, Caserta, Italy <lb/>dg <lb/>Northumbria Healthcare, Newcastle, United Kingdom <lb/>dh <lb/>University Hospital of Královské Vinohrady, Prague, Czech Republic <lb/>di <lb/>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine Eskisehir Osmangazi University, Eskisehir, Turkey <lb/>dj <lb/>Hospital Universitario Virgen del Puerto, Plasencia, Spain <lb/>dk <lb/>Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain <lb/>dl <lb/>Cipto Mangunkusumo General Hospital, Jakarta, Indonesia <lb/>dm <lb/>Hematology and Stem Cell Transplant Unit, Osperadiela University Pisana Company, Pisa, Italy <lb/>dn &quot;Sapienza&quot; University of Rome, Rome, Italy <lb/>do <lb/>Service d&apos;Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne <lb/>Université, Inserm UMRs 938, Paris, France <lb/>dp <lb/>Instituto Nacional do Cancer, Rio de Janeiro, Brazil <lb/>dq <lb/>Faculty of Medicine, University of Chile. Infectious Diseases Unity, Salvador Hospital of Santiago, Santiago de Chile, Chile <lb/>dr <lb/>Azienda ospedaliera &quot;Ospedali Riuniti Villa Sofia-Cervello&quot;, Palermo, Italy <lb/>ds <lb/>Necker-Enfants Malades Hospitals, Paris, France <lb/>dt <lb/>Comenius University and National Cancer Institute, Bratislava, Slovakia <lb/></front>

			<note place="headnote">Articles <lb/></note>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<page>3 <lb/></page>

			<front>du <lb/>Universitätsklinikum Frankfurt am Main, Frankfurt am Main, Germany <lb/>dv <lb/>Hospital Universitario de Cabueñes, Gijón, Spain <lb/>dw <lb/>General Hospital of Thessaloniki &quot;George Papanikolaou&quot;, Thessaloniki, Greece <lb/>dx <lb/>Department of Mental Health and Public Medicine, Universitry of Campania, Naples, Italy <lb/>dy <lb/>Center for Radiology, University Clinical Center of Serbia, Belgrade, Serbia <lb/>dz <lb/>University Hospital Pilsen, Pilsen, Czech Republic <lb/>ea <lb/>Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany <lb/>eb <lb/>Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli -IRCCS, Rome, Italy <lb/>ec <lb/>Institute of Hematology and Blood Transfusion, Prague, Czech Republic <lb/>ed <lb/>Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic <lb/>ee <lb/>University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, <lb/>Germany <lb/>ef <lb/>Hematology Unit, Università Cattolica del Sacro Cuore, Rome, Italy <lb/>Summary <lb/>Background The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to <lb/>compromised immune systems, leading to more severe outcomes and increased mortality. While interventions <lb/>like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their <lb/>benefits for these patients may not be as pronounced. <lb/>Methods The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data <lb/>from hematological malignancy patients since the pandemic&apos;s start worldwide. It spans various global locations, <lb/>allowing comprehensive analysis over the first three years (2020-2022). <lb/>Findings The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 <lb/>cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this <lb/>period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. <lb/>However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors <lb/>contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, <lb/>pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or <lb/>more doses, as well as encountering COVID-19 in 2022, were associated with improved survival. <lb/>Interpretation Patients with hematological malignancies still face elevated risks, despite reductions in critical in-<lb/>fections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The <lb/>study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival <lb/>in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable <lb/>population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-<lb/>19 cases. <lb/>Funding Not applicable. <lb/>Copyright © 2024 Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// <lb/>creativecommons.org/licenses/by/4.0/). <lb/>Keywords: Vaccination; ICU; COVID-19; Haematological malignancy; Immunosuppression <lb/></front>

			<body>Introduction <lb/>Since the emergence of the coronavirus disease 2019 <lb/>(COVID-19) pandemic, hematological malignancy pa-<lb/>tients have faced substantial risks, being highly vulner-<lb/>able to contracting severe acute respiratory syndrome <lb/>coronavirus type 2 (SARS-CoV-2) and experiencing se-<lb/>vere outcomes, including elevated hospitalization rates <lb/>and increased fatality. 1 COVID-19 pandemic reminded <lb/>us the history of other pandemics that happened in the <lb/>last century. In accordance with those, following the <lb/>pandemic phase, we are facing now an epidemic one, <lb/>characterized by less morbidity and severity of the <lb/>virus in the overall population. 2,3 However, hematologi-<lb/>cal malignancy patients still remain at risk of severe <lb/>COVID-19. Despite advancements in medical <lb/>interventions, such as the introduction of anti-SARS-<lb/>CoV-2 vaccines, 4 targeted antivirals, 5 and monoclonal <lb/>antibodies, 6 which have shown promising results in <lb/>reducing the impact of COVID-19 on otherwise healthy <lb/>individuals, the same level of effectiveness cannot <lb/></body>

			<front>eClinicalMedicine <lb/>2024;71: 102553 <lb/>Published Online 18 March <lb/>2024 <lb/>https://doi.org/10. <lb/>1016/j.eclinm.2024. <lb/>102553 <lb/></front>

			<note place="headnote">Articles <lb/></note>

			<page>4 <lb/></page>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<body>always be guaranteed for patients with hematological <lb/>malignancies. <lb/>This discrepancy can be attributed to their compro-<lb/>mised immune system, due to both intrinsic disease <lb/>biology and immunosuppressive treatments, rendering <lb/>them less responsive to vaccines and more susceptible <lb/>to severe COVID-19. 7-16 As such, understanding the <lb/>factors influencing COVID-19 outcomes in this patient <lb/>population becomes paramount in improving their <lb/>overall management and care. Given the unique chal-<lb/>lenges faced by hematological malignancy patients in <lb/>managing COVID-19, identifying risk factors and pro-<lb/>tective factors can significantly inform clinical decision-<lb/>making and enhance patient outcomes. In response to <lb/>the onset of the pandemic, researchers globally engaged <lb/>in a range of analyses across various research levels. <lb/>These encompassed detailed case reports and case se-<lb/>ries, extensive observational studies to derive broader <lb/>insights, and comprehensive literature reviews and <lb/>meta-analyses to synthesize existing knowledge. These <lb/>combined efforts significantly enriched our under-<lb/>standing of the pandemic&apos;s multifaceted implications. 17 <lb/>However, within the context of individuals dealing <lb/>with hematological malignancies, several notable gaps <lb/>in understanding remain; while existing research has <lb/>shed light on specific aspects of the interaction between <lb/>COVID-19 and these malignancies, important questions <lb/>still await exploration. 14,18 The intricate interplay between <lb/>the infection, its progression, and the management <lb/>strategies employed within this patient population ne-<lb/>cessitates further investigation. <lb/>The present study was designed to thoroughly <lb/>investigate the outcomes and potential risk factors <lb/>linked to COVID-19 in patients with hematological <lb/>malignancies from 2020 to 2022, describing not only a <lb/>transversal picture, but also the pandemic trajectory over <lb/>those years in this peculiar patient category. Specifically, <lb/>we aimed to assess the influence of diverse de-<lb/>mographic characteristics, comorbidities, underlying <lb/>malignancies, and vaccination status on mortality rates <lb/>and disease severity. <lb/>Methods <lb/>Study design, patients and procedures <lb/>Participating institutions (n = 152) from 41 countries <lb/>(Supplementary Fig. S1) documented COVID-19 epi-<lb/>sodes diagnosed between January 1, 2020, and <lb/>December 31, 2022 in patients with hematological ma-<lb/>lignancies in the EPICOVIDEHA registry, accessible at <lb/>www.clinicalsurveys.net (EFS Fall 2022, TIVIAN, <lb/>Cologne, <lb/>Germany), <lb/>including <lb/>both <lb/>already <lb/>described 2,7,8,10,11,13,19-33 and undescribed patients. EPI-<lb/>COVIDEHA (National Clinical Trials Identifier, <lb/>Research in context <lb/>Evidence before this study <lb/>Prior to this study, existing research had shed light on the <lb/>risks posed by COVID-19 to hematological malignancy <lb/>patients. Historical data from past pandemics, indicated that <lb/>individuals with hematological malignancies were particularly <lb/>susceptible to severe disease and elevated mortality rates. <lb/>Early in the COVID-19 pandemic, hematological malignancy <lb/>patients faced substantial challenges, with higher <lb/>hospitalization rates and poorer outcomes. Furthermore, the <lb/>emergence of SARS-CoV-2 variants and potential waning <lb/>vaccine efficacy raised concerns about the ongoing <lb/>vulnerability of this population. <lb/>Added value of this study <lb/>This study advances our understanding of COVID-19 <lb/>outcomes in hematological malignancy patients by analyzing <lb/>data spanning from 2020 to 2022, encompassing the <lb/>transition from pandemic to epidemic phases. Leveraging a <lb/>vast dataset from 152 institutions across 41 countries <lb/>through the EPICOVIDEHA registry, this research provides a <lb/>comprehensive examination of risk factors, disease severity, <lb/>and mortality rates. Notably, it highlights the critical role of <lb/>vaccination and early therapeutic interventions, including <lb/>targeted antivirals and monoclonal antibodies, in improving <lb/>prognosis. The study&apos;s insights into the evolving landscape of <lb/>hematological malignancies and the effectiveness of various <lb/>treatment strategies contribute vital knowledge to guide <lb/>clinical decision-making. <lb/>Implications of all the available evidence <lb/>Collectively, the available evidence, including findings from <lb/>this study, underscores the ongoing challenges faced by <lb/>hematological malignancy patients in managing COVID-19. <lb/>Despite the transition from pandemic to epidemic phases, this <lb/>population remains at risk due to their compromised immune <lb/>systems. The implications of this evidence emphasize the <lb/>need for continued vigilance, personalized care, and the <lb/>optimization of vaccination strategies, including booster <lb/>doses. Additionally, the study&apos;s findings underscore the <lb/>significance of early therapeutic interventions and tailored <lb/>treatment approaches based on vaccination status and <lb/>disease severity. As the COVID-19 situation continues to <lb/>evolve, healthcare providers must remain adaptable, <lb/>leveraging the latest evidence to deliver the highest quality <lb/>care to hematological malignancy patients. It is worth noting <lb/>that, even though three years have elapsed since the onset of <lb/>the pandemic, randomized studies in hematology patients <lb/>with COVID-19 are still lacking. Therefore, it is crucial to <lb/>exercise caution with data interpretation as there may be <lb/>aspects where we continue to make errors. <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<page>5 <lb/></page>

			<body>NCT04733729) is an international open web-based reg-<lb/>istry dedicated to adult hematological malignancy pa-<lb/>tients infected with SARS-CoV-2, set by part of the <lb/>European Hematology Association Specialized Working <lb/>Group (EHA-SWG) Infections in Hematology. 30 The <lb/>registry was approved by the local ethics committee of <lb/>the Fondazione Policlinico Universitario Agostino <lb/>Gemelli, IRCCS, Università Cattolica del Sacro Cuore of <lb/>Rome, Italy (Study ID: 3226), and was also approved by <lb/>the respective local ethics committees of each partici-<lb/>pating institution if required. <lb/>To be included in the study, patients had to meet <lb/>certain criteria: they must have had an active hemato-<lb/>logical malignancy within the past 5 years before their <lb/>COVID-19 diagnosis, be aged 18 years or older, have a <lb/>laboratory-confirmed SARS-CoV-2 infection (either by <lb/>polymerase chain reaction [PCR] or rapid antigen test <lb/>kits), and have received a COVID-19 diagnosis between <lb/>January 1, 2020, and December 31, 2022. Patients with <lb/>solid tumors or non-malignant hematological disorders, <lb/>including aplastic anemia, children, patients off-therapy <lb/>or cured for longer than 5 years before COVID-19 <lb/>diagnosis or those with only an imaging procedure-<lb/>based COVID-19 diagnosis were excluded from <lb/>analysis. Data collected for each patient encompassed <lb/>baseline conditions before COVID-19, such as age, <lb/>biological sex, hematological malignancy status at <lb/>COVID-19 diagnosis, and COVID-19 predisposing fac-<lb/>tors. Additionally, details regarding hematological ma-<lb/>lignancy clinical management (i.e., malignancy status, <lb/>type of last malignancy treatment immediately before <lb/>COVID-19 diagnosis), and COVID-19 diagnosis, symp-<lb/>tomatology, prophylaxis and treatments (including type <lb/>number of anti-SARS-CoV-2 vaccines at COVID-19 <lb/>onset and anti-SARS-CoV-2 treatment strategies), and <lb/>outcomes (including mortality and last follow-up date) <lb/>were recorded. The status of hematological malignancy <lb/>at COVID-19 onset was categorized as active (onset and <lb/>refractory/resistant), stable disease, or controlled (com-<lb/>plete and partial response) based on reports from the <lb/>participating institutions. Additionally, patients were <lb/>graded based on the severity of their COVID-19 epi-<lb/>sodes as asymptomatic, mild, severe and critical as <lb/>previously defined. 34 <lb/>To ensure data coherence and completeness, all pa-<lb/>tients were included in a validation process conducted <lb/>by experts in hematological malignancy and infectious <lb/>diseases. During this process, efforts were made to <lb/>reduce data missing completely at random by contacting <lb/>contributors to resolve pending queries. This validation <lb/>process was crucial for maintaining the reliability and <lb/>integrity of the data collected from the EPICOVIDEHA <lb/>registry. 30 If a certain variable had missing data among <lb/>valid cases and was included in regression analyses, <lb/>those patients were also excluded from the analysis. <lb/>Nevertheless, sensitivity analyses were performed <lb/>applying the following methods: series mean, linear <lb/>interpolation, and linear trend at point. <lb/>Study objectives <lb/>The primary objective of the study was to analyze the <lb/>epidemiology and outcomes of hematological malig-<lb/>nancy patients affected by COVID-19 during the period <lb/>2020-2022. Secondary objectives included estimating <lb/>the relative frequency of disease severity, evaluating the <lb/>relative frequency of intensive care unit (ICU) admis-<lb/>sion among participating patients, assessing the overall <lb/>case-fatality rate, exploring the effect of cancer treatment <lb/>phase on patient outcomes, investigating the impact of <lb/>vaccine doses administered on patient outcomes, and <lb/>studying the effect of COVID-19 treatment on patient <lb/>outcomes. <lb/>Statistical analysis <lb/>An a priori sample size calculation was not performed <lb/>as the study was exploratory in nature. Data from <lb/>participating institutions were summarized using fre-<lb/>quencies and percentages for categorical variables, and <lb/>median, interquartile range (IQR), and absolute range <lb/>for continuous variables. A univariable Cox regression <lb/>model was employed to analyze variables suspected to <lb/>influence the mortality of hematological malignancy <lb/>patients with COVID-19. Variables with a p value ≤ 0.1 <lb/>were considered for multivariable analysis, after con-<lb/>firming their clinical relevance. The multivariable Cox <lb/>regression model was calculated using the Wald back-<lb/>ward method. The multivariable Cox regression model <lb/>was constructed using backward elimination with the <lb/>Wald test for variable selection. Exclusion criteria were <lb/>established a priori, guided by a predetermined statis-<lb/>tical significance threshold (p value ≤ 0.05). This <lb/>approach retained variables that significantly contrib-<lb/>uted to the model. Mortality was analyzed using Kaplan-<lb/>Meier survival plots, and a log-rank test was used to <lb/>compare the survival probability of patients included in <lb/>different models. The Cox proportional hazards model <lb/>was applied to analyze variables influencing the mor-<lb/>tality of hematological malignancy patients with <lb/>COVID-19. Assumptions of the model were rigorously <lb/>assessed: tests for proportional hazards (Schoenfeld re-<lb/>sidual test) were conducted to verify the assumption of <lb/>hazard functions&apos; proportionality across strata, and <lb/>scatterplots and diagnostic tools were utilized to confirm <lb/>the linearity of the relationship between the log hazard <lb/>and each covariate (Plot martingale residuals). We <lb/>employed Cox regression analysis to assess the associ-<lb/>ation between various covariates and the survival time of <lb/>patients. The following variables were included in the <lb/>multivariable Cox regression model: sex, age, comor-<lb/>bidities, baseline malignancy, malignancy status at <lb/>COVID-19 diagnosis, vaccine doses before COVID-19, <lb/>COVID-19 diagnosis time periods, COVID-19 <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<page>6 <lb/></page>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<body>symptoms at onset, and stay during COVID-19 episode. <lb/>To account for the potential issue of multiple compari-<lb/>sons, we applied the Bonferroni correction. This <lb/>correction involved adjusting the significance level for <lb/>each individual test to maintain an overall family-wise <lb/>error rate. Specifically, we divided the desired overall <lb/>significance level (p = 0.05) by the number of tests <lb/>conducted. The adjusted significance level was calcu-<lb/>lated as 0.05/9, where 9 represents the number of var-<lb/>iables tested. Therefore, p-values less than 0.0056 were <lb/>considered statistically significant after Bonferroni <lb/>correction. Additionally, we reported Hazard Ratios <lb/>(HR) and 95% Confidence Intervals (CI) to quantify the <lb/>strength and precision of associations. A p value ≤ 0.05 <lb/>was considered statistically significant. The statistical <lb/>analyses were conducted using SPSS version 25.0 <lb/>(SPSS, IBM Corp, Chicago, IL, United States). <lb/>Ethics statement <lb/>The central ethics committee is at Fondazione Policli-<lb/>nico Universitario Agostino Gemelli -IRCCS, Uni-<lb/>versità Cattolica del Sacro Cuore of Rome, Italy (Study <lb/>ID: 3226). Additionally, each participating institution <lb/>may also have a local approval for the research initiative <lb/>as appropriate. The anonymized data that do not contain <lb/>any personally identifiable information from any sour-<lb/>ces implies that the informed consent is not applicable. <lb/>Role of the funding source <lb/>This research did not receive any funding. JSG, FM, LP, <lb/>and OAC had access to and verified all raw data sets and <lb/>made the decision to submit the manuscript. The cor-<lb/>responding author can provide the data supporting the <lb/>findings of this study upon a reasonable request. <lb/>Results <lb/>Out of the 9416 COVID-19 episodes diagnosed between <lb/>January 1, 2020, and December 31, 2022 and docu-<lb/>mented in the EPICOVIDEHA registry, 8767 were set <lb/>valid and included to analysis. Out of the 649 cases set <lb/>invalid, 179 patients had non-malignant hematological <lb/>disorders or solid tumors, 135 patients were excluded as <lb/>their diagnosis of COVID-19 was based on clinical <lb/>criteria rather than laboratory confirmation, 93 patients <lb/>had hematological malignancies diagnosed longer than <lb/>six months after contracting COVID-19, 87 patients had <lb/>been off therapy for more than 5 years, 86 cases were <lb/>removed due to incomplete information, 55 patients <lb/>were below the age of 18, and 14 cases had double <lb/>entries. <lb/>The overall sample included 8767 patients, with <lb/>nearly 60% (n = 5119) being male. The median age was <lb/>65 years (IQR: 54-75); the youngest patient was 18, and <lb/>the oldest was 106, with majority of patients (79.6%, <lb/>n = 6975) older than 50 years. Age groups showed sta-<lb/>tistically significant differences in mortality rates <lb/>(p &lt; 0.0001) (Table 1, Supplementary Tables S1-S6). <lb/>Regarding comorbidities, 70.8% (n = 6205) of the pa-<lb/>tients had 0-1 comorbidities, with a significantly lower <lb/>mortality rate as compared to those with 2 or more <lb/>comorbidities (p &lt; 0.0001). The most common comor-<lb/>bidities observed were chronic cardiopathy (35.3%, <lb/>n = 3095), diabetes mellitus (14.5%, n = 1268), and <lb/>chronic pulmonary disease (13.2%, n = 1157) <lb/>(Supplementary Fig. S2A). As for the underlying ma-<lb/>lignancies, non-Hodgkin lymphoma (31.2%, n = 2731) <lb/>and plasma cells disorders (17.6%, n = 1546) were the <lb/>most prevalent (Supplementary Fig. S2B). However, <lb/>myelodysplastic syndrome (21.2%, n = 121/572), acute <lb/>leukemia (19.0%, n = 280/1475), and chronic lymphoid <lb/>leukemia (18.1%, n = 210/1163) exhibited the highest <lb/>mortality rates, all of which were statistically significant <lb/>(p &lt; 0.0001) (Fig. 1A). Almost half of the patients <lb/>(47.1%, n = 4131) had controlled malignancy. Among <lb/>them, patients with controlled malignancy (10.2%, <lb/>n = 420/4131) and stable malignancy (13.6%, n = 230/ <lb/>1688) experienced lower mortality rates compared to <lb/>those with active malignancy (25.5%, n = 676/2646), <lb/>p &lt; 0.0001 (Fig. 1B, Table 1, Supplementary Tables S1-<lb/>S6). Regarding the vaccination status against SARS-<lb/>CoV-2, 64.5% (n = 5658) of patients were unvaccinated <lb/>as they were diagnosed with COVID-19 before the <lb/>availability of the first vaccines, and this cohort exhibited <lb/>the highest mortality rate at 20.8%. <lb/>Mortality rates decreased with an increasing number <lb/>of anti-SARS-CoV-2 vaccine doses administered before <lb/>COVID-19 diagnosis (1 dose: 10.3%, n = 22/214; 5 <lb/>doses: 0.0%, n = 0/23), with a statistically significant <lb/>difference (p &lt; 0.001) (Table 1, Supplementary <lb/>Tables S1-S6). Six in ten patients (60.0%, n = 5263) <lb/>experienced pulmonary symptoms at the onset of <lb/>COVID-19. Overall, 36.5% (n = 3197) of patients had <lb/>asymptomatic or mild infection (Fig. 2A). One third of <lb/>the patients (35.2%, n = 3084) were managed at home, <lb/>while 64.8% (n = 5683) were admitted to the hospital at <lb/>any point during COVID-19. Among the hospitalized <lb/>patients, 16.1% required admission to the ICU (Table 1, <lb/>Supplementary Tables S1-S6). The overall 30-day mor-<lb/>tality rate was 16.1% (n = 1415/8767, Fig. 2B), with <lb/>COVID-19 being associated with mortality in 89.8% of <lb/>these cases (Fig. 2C, Table 1, Supplementary <lb/>Tables S1-S6). The following factors linked to <lb/>increased mortality: a) older age (aHR 1.037, 95% CI <lb/>1.032-1.042, p &lt; 0.0001), b) 2 or more comorbidities at <lb/>COVID-19 onset (aHR 1.244, 95% CI 1.117-1.386, <lb/>p &lt; 0.0001), c) active malignancy (aHR 1.832, 95% CI <lb/>1.617-2.075, p &lt; 0.0001), d) pulmonary symptoms at <lb/>COVID-19 onset, either alone (aHR 1.299, 95% CI <lb/>1.095-1.541, p = 0.0026) or in combination with <lb/>extrapulmonary symptoms (aHR 1.168, 95% CI <lb/>0.978-1.396, p = 0.08), and e) hospitalized patients <lb/>without ICU (aHR 12.767, 95% CI 8.723-18.684, <lb/>p &lt; 0.0001) and patients admitted to the ICU (aHR <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<page>7 <lb/></page>

			<body>Total <lb/>Alive <lb/>Dead <lb/>p value <lb/>n <lb/>% <lb/>n <lb/>% <lb/>n <lb/>% <lb/>Sex <lb/>0.08 <lb/>Female <lb/>3648 <lb/>41.6 <lb/>3089 <lb/>84.7 <lb/>559 <lb/>15.3 <lb/>Male <lb/>5119 <lb/>58.4 <lb/>4263 <lb/>83.3 <lb/>856 <lb/>16.7 <lb/>Age <lb/>65 (54-75) <lb/>[18-106] <lb/>64 (52-73) <lb/>[18-97] <lb/>73 (63-80) <lb/>[18-106] <lb/>&lt;0.0001 <lb/>18-25 years old <lb/>268 <lb/>3.1 <lb/>244 <lb/>91.0 <lb/>24 <lb/>9.0 <lb/>26-50 years old <lb/>1524 <lb/>17.4 <lb/>1411 <lb/>92.6 <lb/>113 <lb/>7.4 <lb/>51-69 years old <lb/>3517 <lb/>40.1 <lb/>3094 <lb/>88.0 <lb/>423 <lb/>12.0 <lb/>&gt;69 years old <lb/>3458 <lb/>39.4 <lb/>2603 <lb/>75.3 <lb/>855 <lb/>24.7 <lb/>Comorbidities at COVID-19 onset <lb/>0-1 comorbidities <lb/>6205 <lb/>70.8 <lb/>5401 <lb/>87.0 <lb/>804 <lb/>13.0 <lb/>&lt;0.0001 <lb/>2+ comorbidities <lb/>2562 <lb/>29.2 <lb/>1951 <lb/>76.2 <lb/>611 <lb/>23.8 <lb/>Chronic cardiopathy <lb/>3095 <lb/>35.3 <lb/>2422 <lb/>78.3 <lb/>673 <lb/>21.7 <lb/>&lt;0.0001 <lb/>Chronic pulmonary disease <lb/>1157 <lb/>13.2 <lb/>892 <lb/>77.1 <lb/>265 <lb/>22.9 <lb/>&lt;0.0001 <lb/>Diabetes mellitus <lb/>1268 <lb/>14.5 <lb/>979 <lb/>77.2 <lb/>289 <lb/>22.8 <lb/>&lt;0.0001 <lb/>Liver disease <lb/>355 <lb/>4.0 <lb/>267 <lb/>75.2 <lb/>88 <lb/>24.8 <lb/>&lt;0.0001 <lb/>Renal impairment <lb/>648 <lb/>7.4 <lb/>456 <lb/>70.4 <lb/>192 <lb/>29.6 <lb/>&lt;0.0001 <lb/>Smoking history <lb/>978 <lb/>11.2 <lb/>781 <lb/>79.9 <lb/>197 <lb/>20.1 <lb/>0.00031 <lb/>Baseline hematological malignancy <lb/>&lt;0.0001 <lb/>Hodgkin lymphoma <lb/>354 <lb/>4.0 <lb/>328 <lb/>92.7 <lb/>26 <lb/>7.3 <lb/>Chronic lymphoid leukemia <lb/>1163 <lb/>13.3 <lb/>953 <lb/>81.9 <lb/>210 <lb/>18.1 <lb/>Acute leukemia <lb/>1475 <lb/>16.8 <lb/>0 <lb/>0.0 <lb/>280 <lb/>19.0 <lb/>Acute myeloid leukemia <lb/>1060 <lb/>12.1 <lb/>824 <lb/>77.7 <lb/>236 <lb/>22.3 <lb/>Acute lymphoid leukemia <lb/>415 <lb/>4.7 <lb/>371 <lb/>89.4 <lb/>44 <lb/>10.6 <lb/>Non-Hodgkin lymphoma <lb/>2731 <lb/>31.2 <lb/>2315 <lb/>84.8 <lb/>416 <lb/>15.2 <lb/>Chronic myeloid malignancies <lb/>867 <lb/>9.9 <lb/>780 <lb/>90.0 <lb/>87 <lb/>10.0 <lb/>Chronic myeloid leukemia <lb/>334 <lb/>3.8 <lb/>313 <lb/>93.7 <lb/>21 <lb/>6.3 <lb/>Essential thrombocythemia <lb/>142 <lb/>1.6 <lb/>131 <lb/>92.3 <lb/>11 <lb/>7.7 <lb/>Myelofibrosis <lb/>233 <lb/>2.7 <lb/>190 <lb/>81.5 <lb/>43 <lb/>18.5 <lb/>Polycythemia vera <lb/>134 <lb/>1.5 <lb/>123 <lb/>91.8 <lb/>11 <lb/>8.2 <lb/>Systemic mastocytosis <lb/>24 <lb/>0.3 <lb/>23 <lb/>95.8 <lb/>1 <lb/>4.2 <lb/>Plasma cell disorders <lb/>1546 <lb/>17.6 <lb/>1281 <lb/>82.9 <lb/>265 <lb/>17.1 <lb/>Multiple myeloma <lb/>1513 <lb/>17.3 <lb/>1249 <lb/>82.6 <lb/>264 <lb/>17.4 <lb/>Amyloid light-chain amyloidosis <lb/>33 <lb/>0.4 <lb/>32 <lb/>97.0 <lb/>1 <lb/>3.0 <lb/>Myelodysplastic syndrome <lb/>572 <lb/>6.5 <lb/>451 <lb/>78.8 <lb/>121 <lb/>21.2 <lb/>Hairy cell leukemia <lb/>59 <lb/>0.7 <lb/>49 <lb/>83.1 <lb/>10 <lb/>16.9 <lb/>Baseline hematological malignancy status at COVID-19 onset <lb/>&lt;0.0001 <lb/>Controlled malignancy <lb/>4131 <lb/>47.1 <lb/>3711 <lb/>89.8 <lb/>420 <lb/>10.2 <lb/>Complete remission <lb/>2717 <lb/>31.0 <lb/>2502 <lb/>92.1 <lb/>215 <lb/>7.9 <lb/>Partial remission <lb/>1414 <lb/>16.1 <lb/>1209 <lb/>85.5 <lb/>205 <lb/>14.5 <lb/>Stable malignancy <lb/>1688 <lb/>19.3 <lb/>1458 <lb/>86.4 <lb/>230 <lb/>13.6 <lb/>Active malignancy <lb/>2646 <lb/>30.2 <lb/>1970 <lb/>74.5 <lb/>676 <lb/>25.5 <lb/>Onset <lb/>1553 <lb/>17.7 <lb/>1195 <lb/>76.9 <lb/>358 <lb/>23.1 <lb/>Refractory/Resistant <lb/>1093 <lb/>12.5 <lb/>775 <lb/>70.9 <lb/>318 <lb/>29.1 <lb/>Unknown <lb/>302 <lb/>3.4 <lb/>213 <lb/>70.5 <lb/>89 <lb/>29.5 <lb/>SARS-CoV-2 vaccination at COVID-19 onset <lb/>&lt;0.0001 <lb/>0 doses <lb/>5658 <lb/>64.5 <lb/>4480 <lb/>79.2 <lb/>1178 <lb/>20.8 <lb/>1-2 doses <lb/>1328 <lb/>15.1 <lb/>1192 <lb/>89.8 <lb/>136 <lb/>10.2 <lb/>1 dose <lb/>214 <lb/>2.4 <lb/>192 <lb/>89.7 <lb/>22 <lb/>10.3 <lb/>2 doses <lb/>1114 <lb/>12.7 <lb/>1000 <lb/>89.8 <lb/>114 <lb/>10.2 <lb/>(Table 1 continues on next page) <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<page>8 <lb/></page>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<body>33.684, 95% CI 22.915-49.514, p &lt; 0.0001). On the other <lb/>hand, certain factors were associated with reduced <lb/>mortality, such as: a) vaccination with 1-2 doses (aHR <lb/>0.681, 95% CI 0.546-0.850, p &lt; 0.00066) or with 3 or <lb/>more (aHR 0.451, 95% CI 0.35-0.582, p &lt; 0.0001), b) <lb/>COVID-19 diagnosis later in the pandemic, specifically <lb/>between July-December 2020 (aHR 0.802, 95% CI <lb/>0.701-0.917, p &lt; 0.0012), January-June 2021 (aHR <lb/>0.796, 95% CI 0.662-0.958, p = 0.015) and July-<lb/>December 2022 (aHR 0.427, 95% CI 0.282-0.647, <lb/>p &lt; 0.000059) (Table 2). Sensitivity analyses were con-<lb/>ducted to address the absence of data on observation <lb/>days from certain patients. The outcomes obtained <lb/>showed consistency and endorsed identical variables as <lb/>either risk or protective factors, in alignment with the <lb/>aforementioned paragraph. Comprehensive results can <lb/>be found in Supplementary Tables S7-S9. <lb/>Changes over time <lb/>During the study period from 2020 to 2022, the patient <lb/>distribution in terms of sex, age group, number of <lb/>comorbidities (Supplementary Fig. S2A), and malig-<lb/>nancy status at COVID-19 onset or last malignancy <lb/>treatment remained stable (Supplementary Fig. S2C). <lb/>Non-Hodgkin lymphoma exhibited stability, while there <lb/>was an observed rise in the prevalence of plasma cell <lb/>disorders, along with acute leukemia. Conversely, mye-<lb/>lodysplastic syndrome and chronic myeloid malig-<lb/>nancies demonstrated a decline (Supplementary <lb/>Fig. S2B). Moreover, there was an increase in the <lb/>number of vaccinated patients, those not requiring <lb/>hospitalization and managing their condition at home <lb/>during the COVID-19 episode (Supplementary <lb/>Tables S1-S6). Alongside this, there was a notable <lb/>reduction in the severity of COVID-19 cases (Fig. 2A, <lb/>Supplementary Tables S1-S6). <lb/>A decline in COVID-19-related mortality across all <lb/>severity degrees was observed (Supplementary <lb/>Tables S1-S6), as well as in all-cause mortality <lb/>(Fig. 2B). Furthermore, this decrease in mortality was <lb/>evident when considering type of baseline malignancy <lb/>(Fig. 2A), malignancy treatment (Fig. 1C), malignancy <lb/>status at COVID-19 onset (Fig. 1B), and the cause of <lb/>death (Fig. 2C). Among causes of death there was a <lb/>decrease in the influence of COVID-19-related factors <lb/>and a corresponding increase in the impact of hemato-<lb/>logical malignancy. This reduction in mortality rates was <lb/>evident in the overall analysis but was more limited for <lb/>in-hospital and critical patients. <lb/>Moreover, the study demonstrated a significant in-<lb/>crease in the likelihood of surviving up to day 30 after <lb/>being diagnosed with COVID-19, especially for patients <lb/>Total <lb/>Alive <lb/>Dead <lb/>p value <lb/>n <lb/>% <lb/>n <lb/>% <lb/>n <lb/>% <lb/>(Continued from previous page) <lb/>3+ doses <lb/>1781 <lb/>20.3 <lb/>1680 <lb/>94.3 <lb/>101 <lb/>5.7 <lb/>3 doses <lb/>1484 <lb/>16.9 <lb/>1391 <lb/>93.7 <lb/>93 <lb/>6.3 <lb/>4 doses <lb/>274 <lb/>3.1 <lb/>266 <lb/>97.1 <lb/>8 <lb/>2.9 <lb/>5 doses <lb/>23 <lb/>0.3 <lb/>23 <lb/>100.0 <lb/>0 <lb/>0.0 <lb/>COVID-19 symptoms at onset <lb/>&lt;0.0001 <lb/>Screening <lb/>1787 <lb/>20.4 <lb/>1605 <lb/>89.8 <lb/>182 <lb/>10.2 <lb/>Extrapulmonary only <lb/>1717 <lb/>19.6 <lb/>1554 <lb/>90.5 <lb/>163 <lb/>9.5 <lb/>Extrapulmonary + pulmonary <lb/>2237 <lb/>25.5 <lb/>1781 <lb/>79.6 <lb/>456 <lb/>20.4 <lb/>Pulmonary only <lb/>3026 <lb/>34.5 <lb/>2412 <lb/>79.7 <lb/>614 <lb/>20.3 <lb/>COVID-19-episode severity <lb/>&lt;0.0001 <lb/>Asymptomatic <lb/>1546 <lb/>17.6 <lb/>1442 <lb/>93.3 <lb/>104 <lb/>6.7 <lb/>Mild infection <lb/>1651 <lb/>18.8 <lb/>1545 <lb/>93.6 <lb/>106 <lb/>6.4 <lb/>Severe infection <lb/>4291 <lb/>48.9 <lb/>3655 <lb/>85.2 <lb/>636 <lb/>14.8 <lb/>Critical infection <lb/>1279 <lb/>14.6 <lb/>710 <lb/>55.5 <lb/>569 <lb/>44.5 <lb/>Stay during COVID-19 <lb/>&lt;0.0001 <lb/>Home <lb/>3084 <lb/>35.2 <lb/>3056 <lb/>99.1 <lb/>28 <lb/>0.9 <lb/>Hospital no ICU <lb/>4404 <lb/>50.2 <lb/>3586 <lb/>81.4 <lb/>818 <lb/>18.6 <lb/>Hospital ICU <lb/>1279 <lb/>14.6 <lb/>710 <lb/>55.5 <lb/>569 <lb/>44.5 <lb/>Mortality, d30 <lb/>1415 <lb/>16.1 <lb/>0 <lb/>0.0 <lb/>1415 <lb/>100.0 <lb/>Reason for mortality <lb/>COVID-19 <lb/>904 <lb/>10.3 <lb/>0 <lb/>0.0 <lb/>904 <lb/>63.9 <lb/>COVID-19 + hematological malignancy <lb/>367 <lb/>4.2 <lb/>0 <lb/>0.0 <lb/>367 <lb/>25.9 <lb/>Hematological malignancies ± other reasons <lb/>144 <lb/>1.6 <lb/>0 <lb/>0.0 <lb/>144 <lb/>10.2 <lb/>COVID-19, coronavirus disease 2019; ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. <lb/>Table 1: Characteristics of EPICOVIDEHA 2020-2022 patients. <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<page>9 <lb/></page>

			<body>Fig. 1: EPICOVIDEHA 2020-2022 patients: mortality per baseline malignancy, malignancy status at COVID-19 onset, and last malignancy <lb/>treatment. A) 2020-2022 mortality per baseline malignancy. B) 2020-2022 mortality per malignancy status at COVID-19 onset. C) 2020-2022 <lb/>mortality per last malignancy treatmentAllo, allogeneic; auto, autologous; CAR-T, chimeric antigen T cell receptors; HSCT, hematopoietic stem <lb/>cell transplantation. <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<page>10 <lb/></page>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<body>who received their diagnosis later in the pandemic <lb/>(Fig. 3A). Vaccinated individuals also had considerably <lb/>higher survival rates when compared to the unvacci-<lb/>nated (Fig. 3B). This increase in survival probability was <lb/>notable regardless of initial malignancy status <lb/>(Supplementary Fig. S3A), or setting during their <lb/>COVID-19 episode at home, in hospital, or ICU <lb/>(Supplementary Fig. S3B). <lb/>The impact of COVID-19 treatment on survival was <lb/>substantial. For unvaccinated patients, those with the <lb/>highest likelihood of survival were either those who did <lb/>not require any COVID-19 treatment or those who <lb/>received monoclonal antibodies alone or in combination <lb/>with antiviral medications (Fig. 3C). Among patients <lb/>who had received 1-2 vaccine doses, highest survival <lb/>probability was with no treatment required or treatment <lb/>involving monoclonal antibodies and antivirals alone or <lb/>in combination (Fig. 3D). Finally, for patients who had <lb/>received 3 or more vaccinations, various treatment op-<lb/>tions showed varying degrees of effectiveness, except for <lb/>corticosteroids alone (Fig. 3E). <lb/>Discussion <lb/>This manuscript, encompassing data from 2020 to 2022, <lb/>aims to shed light on the significant impact of COVID-<lb/>19 on hematological malignancy patients, with a <lb/>particular emphasis on mortality, which was specifically <lb/>pronounced in the year 2020. The study uncovers <lb/>several critical factors that influence negatively COVID-<lb/>19 outcomes in this patient population, with age, <lb/>comorbidities, and malignancy status emerging as key <lb/>risk factors for mortality. In contrast, the introduction of <lb/>COVID-19 vaccines and the progression of the <lb/>pandemic into later phases, leading to improved pre-<lb/>ventive and targeted treatment options, heightened <lb/>awareness, earlier treatment initiation, and a broader <lb/>knowledge base overall, are associated with reduced <lb/>mortality. Additionally, the study delves into the <lb/>evolving landscape of hematological malignancies most <lb/>closely linked to COVID-19 occurrences, revealing dy-<lb/>namic shifts in prevalence that necessitate adaptable <lb/>treatment strategies to address emerging challenges. <lb/>These findings underscore the significance of tailored <lb/>care, ongoing monitoring, and flexibility in managing <lb/>patients with hematological malignancies in the ever-<lb/>evolving context of COVID-19. <lb/>The evolving landscape of hematological malig-<lb/>nancies presents a noteworthy development. While the <lb/>number of reported COVID-19 cases in non-Hodgkin <lb/>lymphoma patients remained consistent over time, <lb/>there was an increase in reported cases among in-<lb/>dividuals with plasma cell disorders and acute leukemia. <lb/>Conversely, the number of cases in patients with mye-<lb/>lodysplastic syndrome and chronic myeloid malig-<lb/>nancies decreased. These shifts underscore the <lb/>importance of continuously adapting treatment strate-<lb/>gies to address new challenges and devising personal-<lb/>ized approaches to manage patients with hematological <lb/>malignancies during a pandemic. Taken together, these <lb/>data reveal an overall predominance of COVID-19 di-<lb/>agnoses among patients with lymphoid malignancies <lb/>Fig. 1: Continued <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<page>11 <lb/></page>

			<body>throughout the years. This could potentially be attrib-<lb/>uted to the well-documented lower efficacy of anti-<lb/>SARS-CoV-2 vaccines and their reduced development <lb/>of immunity in this patient population. 7,9,14 <lb/>The most encouraging findings center around the <lb/>effects of COVID-19 vaccination and treatment strate-<lb/>gies. During the research period, vaccination emerged <lb/>as a significant approach in mitigating the severity of <lb/>Fig. 2: EPICOVIDEHA 2020-2022 patients: COVID-19 severity prevalence and mortality rate, overall mortality rate, mortality per malignancy <lb/>status at COVID-19 onset, and mortality per reason for mortality. A) 2020-2022 COVID-19 severity prevalence. B) 2020-2022 mortality rate <lb/>overall. C) 2020-2022 mortality rate per reason for mortality. COVID-19, coronavirus disease 2019. *Arrows in this figure indicate the date when <lb/>the respective medical product was made available for the very first time in the world. This is applicable to some of the contributing institutions, <lb/>not to them all. <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<page>12 <lb/></page>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<body>COVID-19, even in patients with hematological malig-<lb/>nancies. 7 Although it was not possible to establish <lb/>complete immunity due to data limitations, the data did <lb/>indicate a dose-response relationship. Patients who had <lb/>received a greater number of vaccine doses before being <lb/>diagnosed with COVID-19 experienced significantly <lb/>lower mortality rates, affirming the findings from our <lb/>initial report. 31 This underscores the importance of <lb/>vaccination programs and booster doses in offering the <lb/>utmost protection to this highly vulnerable group. <lb/>Additionally, early therapeutic strategies, particularly the <lb/>use of targeted antivirals and monoclonal antibodies, <lb/>were crucial in enhancing patient outcomes. 35-37 These <lb/>early treatments not only reduced the severity of the <lb/>illness but also led to decreased mortality rates. 10,11,18 <lb/>The study also revealed a notable decline in the <lb/>severity of COVID-19 cases as time progressed. This <lb/>trend aligns with the broader context of the pandemic, <lb/>where advancements in treatment, including the early <lb/>administration of drugs, and the implementation of <lb/>prophylaxis and vaccine programs ultimately led to <lb/>milder cases. 38 The reduction in COVID-19 mortality <lb/>across various severity levels, all-cause mortality, and <lb/>factors contributing to mortality is a testament to the <lb/>collaborative efforts of the medical community. Patients <lb/>have reaped the rewards of enhanced treatments and <lb/>more effective supportive care, as healthcare pro-<lb/>fessionals have become increasingly skilled at early <lb/>detection and intervention. These trends underscore the <lb/>adaptability and resilience of the medical community in <lb/>the midst of a rapidly evolving health crisis. <lb/>Nonetheless, it is important to remain vigilant, as the <lb/>severity levels in hematological malignancy patients are <lb/>still elevated compared to the general population. <lb/>One of the most striking findings in the dataset is the <lb/>increase in survival probability at day 30 following a <lb/>COVID-19 diagnosis. Patients diagnosed later in the <lb/>pandemic showed notably higher survival rates. Vacci-<lb/>nated individuals also exhibited significantly improved <lb/>survival rates. This proves that not only have medical <lb/>approaches advanced, but patient outcomes have <lb/>benefited from the accumulation of clinical experience <lb/>and learning over time. Moreover, the impact of <lb/>COVID-19-specific treatments on survival should not be <lb/>underestimated. The study revealed that among unvac-<lb/>cinated patients, those who received monoclonal anti-<lb/>bodies alone or in combination with antiviral <lb/>medications had the highest likelihood of survival, <lb/>aligning with findings from studies conducted on the <lb/>general population. 39 This underscores the importance <lb/>of tailoring treatment options based on vaccination sta-<lb/>tus and the severity of illness of each patient. <lb/>Despite positive trends and progress, the challenge of <lb/>COVID-19 persists for hematological malignancy pa-<lb/>tients, particularly those who are in-hospital and critically <lb/>ill. While the World Health Organization (WHO) has <lb/>declared the pandemic phase to be over, concerns still <lb/>loom regarding the virus&apos;s tendency to mutate and the <lb/>potential reduction in the effectiveness of preventive <lb/>measures. The EPICOVIDEHA registry has demon-<lb/>strated its value as a valuable tool for surveillance and <lb/>research in this regard. 2,7,8,10,11,13,19-21,24-26,28,29,31,33 As the <lb/>Fig. 2: Continued. <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<page>13 <lb/></page>

			<body>Univariable <lb/>Multivariable <lb/>p value <lb/>HR <lb/>95% CI <lb/>p value <lb/>HR <lb/>95% CI <lb/>Lower <lb/>Upper <lb/>Lower <lb/>Upper <lb/>Sex <lb/>Female <lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>Male <lb/>0.08 <lb/>1.100 <lb/>0.988 <lb/>1.223 <lb/>0.99 <lb/>1.001 <lb/>0.899 <lb/>1.115 <lb/>Age <lb/>&lt;0.0001 <lb/>1.037 <lb/>1.033 <lb/>1.041 <lb/>&lt;0.0001 <lb/>1.037 <lb/>1.032 <lb/>1.042 <lb/>Comorbidities <lb/>0-1 comorbidities <lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>2+ comorbidities <lb/>&lt;0.0001 <lb/>1.917 <lb/>1.726 <lb/>2.130 <lb/>&lt;0.0001 <lb/>1.244 <lb/>1.117 <lb/>1.386 <lb/>Baseline malignancy <lb/>Hodgkin lymphoma <lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>Chronic lymphoid leukemia <lb/>&lt;0.0001 <lb/>2.638 <lb/>1.755 <lb/>3.965 <lb/>0.52 <lb/>0.874 <lb/>0.578 <lb/>1.32 <lb/>Acute leukemia <lb/>&lt;0.0001 <lb/>2.818 <lb/>1.885 <lb/>4.211 <lb/>0.08 <lb/>1.431 <lb/>0.956 <lb/>2.141 <lb/>Non-Hodgkin lymphoma <lb/>0.00015 <lb/>2.152 <lb/>1.448 <lb/>3.198 <lb/>0.49 <lb/>0.868 <lb/>0.583 <lb/>1.293 <lb/>Chronic myeloid malignancies <lb/>0.12 <lb/>1.417 <lb/>0.914 <lb/>2.196 <lb/>0.20 <lb/>0.747 <lb/>0.479 <lb/>1.163 <lb/>Plasma cell disorders <lb/>&lt;0.0001 <lb/>2.503 <lb/>1.673 <lb/>3.744 <lb/>0.71 <lb/>1.08 <lb/>0.72 <lb/>1.621 <lb/>Myelodysplastic syndrome <lb/>&lt;0.0001 <lb/>3.163 <lb/>2.071 <lb/>4.832 <lb/>0.98 <lb/>0.985 <lb/>0.64 <lb/>1.517 <lb/>Hairy cell leukemia <lb/>0.018 <lb/>2.416 <lb/>1.165 <lb/>5.011 <lb/>0.51 <lb/>0.781 <lb/>0.376 <lb/>1.623 <lb/>Malignancy status at COVID-19 diagnosis <lb/>Controlled malignancy <lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>Stable malignancy <lb/>&lt;0.0001 <lb/>1.394 <lb/>1.187 <lb/>1.637 <lb/>0.21 <lb/>1.115 <lb/>0.94 <lb/>1.321 <lb/>Active malignancy <lb/>&lt;0.0001 <lb/>2.731 <lb/>2.418 <lb/>3.085 <lb/>&lt;0.0001 <lb/>1.832 <lb/>1.617 <lb/>2.075 <lb/>Vaccine doses before COVID-19 <lb/>0 doses <lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>1-2 doses <lb/>&lt;0.0001 <lb/>0.503 <lb/>0.421 <lb/>0.601 <lb/>0.00067 <lb/>0.681 <lb/>0.546 <lb/>0.850 <lb/>3+ doses <lb/>&lt;0.0001 <lb/>0.286 <lb/>0.233 <lb/>0.350 <lb/>&lt;0.0001 <lb/>0.451 <lb/>0.35 <lb/>0.582 <lb/>COVID-19 diagnosis <lb/>January-June 2020 <lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>July-December 2020 <lb/>&lt;0.0001 <lb/>0.577 <lb/>0.506 <lb/>0.657 <lb/>0.0012 <lb/>0.802 <lb/>0.701 <lb/>0.917 <lb/>January-June 2021 <lb/>&lt;0.0001 <lb/>0.618 <lb/>0.517 <lb/>0.740 <lb/>0.015 <lb/>0.796 <lb/>0.662 <lb/>0.958 <lb/>July-December 2021 <lb/>&lt;0.0001 <lb/>0.470 <lb/>0.388 <lb/>0.567 <lb/>0.59 <lb/>0.938 <lb/>0.745 <lb/>1.18 <lb/>January-June 2022 <lb/>&lt;0.0001 <lb/>0.322 <lb/>0.273 <lb/>0.381 <lb/>0.08 <lb/>0.833 <lb/>0.679 <lb/>1.021 <lb/>July-December 2022 <lb/>&lt;0.0001 <lb/>0.132 <lb/>0.089 <lb/>0.197 <lb/>&lt;0.0001 <lb/>0.427 <lb/>0.282 <lb/>0.647 <lb/>COVID-19 symptoms at onset <lb/>Screening <lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>Extrapulmonary only <lb/>0.49 <lb/>0.928 <lb/>0.751 <lb/>1.146 <lb/>0.13 <lb/>0.848 <lb/>0.685 <lb/>1.049 <lb/>Extrapulmonary + pulmonary <lb/>&lt;0.0001 <lb/>2.131 <lb/>1.794 <lb/>2.530 <lb/>0.09 <lb/>1.168 <lb/>0.978 <lb/>1.396 <lb/>Pulmonary only <lb/>&lt;0.0001 <lb/>2.149 <lb/>1.821 <lb/>2.535 <lb/>0.0026 <lb/>1.299 <lb/>1.095 <lb/>1.541 <lb/>Stay during COVID-19 episode <lb/>Home <lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>-<lb/>Hospital, no ICU <lb/>&lt;0.0001 <lb/>22.360 <lb/>15.342 <lb/>32.589 <lb/>&lt;0.0001 <lb/>12.767 <lb/>8.723 <lb/>18.684 <lb/>Hospital, ICU <lb/>&lt;0.0001 <lb/>57.020 <lb/>39.015 <lb/>83.335 <lb/>&lt;0.0001 <lb/>33.684 <lb/>22.915 <lb/>49.514 <lb/>COVID-19, coronavirus disease 2019; HR, hazard ratio; ICU, intensive care unit. After applying the Bonferroni correction, variables with a p &lt; 0.0056 were considered as <lb/>statistically significant. The variables age, comorbidities, malignancy status at COVID-19 diagnosis, vaccine doses before COVID-19, COVID-19 diagnosis (item July-December <lb/>2020), COVID-19 symptoms at onset, and stay during COVID-19 episode remain significant. Other variables do not reach the adjusted significance level. To address missing <lb/>data, sensitivity analyses were performed. In Supplementary Table S7 missing values in Days from COVID-19 diagnosis were input with the series mean method, in <lb/>Supplementary Table S8 missing values in Days from COVID-19 diagnosis were input with the linear interpolation method, and in Supplementary Table S9 missing values in <lb/>Days from COVID-19 diagnosis were input with the linear trend at point method. Hazard function proportionality over the time t and lineal relationship between the log <lb/>hazard and each covariate in the model depicted in the table have been analyzed and are presented in Supplementary Figs. S4-S7. Supplementary Fig. S4 presents the <lb/>proportional hazard evaluation of the variables presented in Table 2. p values for the Schoenfeld residual test are as follows: age p = 0.09 (proportional), baseline malignancy <lb/>p = 0.0057 (non-proportional), month of COVID-19 diagnosis p &lt; 0.0001 (non-proportional), stay during COVID-19 episodes p &lt; 0.0001 (non-proportional), vaccine doses <lb/>before COVID-19 p = 0.0027 (non-proportional), comorbidities p = 0.88 (proportional), COVID-19 symptoms at onset p = 0.0018 (non-proportional), sex p = 0.68 <lb/>(proportional), and malignancy status at COVID-19 diagnosis p = 0.11 (proportional). Plot martingale residuals are presented in Supplementary Fig. S5. Sensitivity analyses <lb/>were performed for the proportional hazard evaluation, reducing the answer categories presented in Table 2. These are shown in Supplementary Fig. S6. p values for the <lb/>Schoenfeld residual test are as follows: age p = 0.09 (proportional), baseline malignancy p = 0.0054 (non-proportional), month of COVID-19 diagnosis p &lt; 0.0001 (non-<lb/>proportional), stay during COVID-19 episodes p &lt; 0.0001 (non-proportional), vaccine doses before COVID-19 p = 0.00071 (non-proportional), comorbidities p = 0.88 <lb/>(proportional), COVID-19 symptoms at onset p = 0.00086 (non-proportional), sex p = 0.69 (proportional), and malignancy status at COVID-19 diagnosis p = 0.11 <lb/>(proportional). Plot martingale residuals are presented in Supplementary Fig. S7. <lb/>Table 2: Factors associated with mortality in EPICOVIDEHA 2020-2022 patients. <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<page>14 <lb/></page>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<note place="headnote">Articles <lb/></note>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<page>15 <lb/></page>

			<body>virus continues to evolve, vigilance and adaptability are <lb/>of paramount importance. In the midst of a constantly <lb/>shifting landscape, continuous surveillance, research, <lb/>and adaptation will be crucial to ensure that patients with <lb/>hematological malignancies receive the highest quality <lb/>of care. Ongoing monitoring and adjustment of strate-<lb/>gies are needed to address the potential impact of viral <lb/>mutations and any declines in the effectiveness of <lb/>Fig. 3: Continued. <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<page>16 <lb/></page>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<body>preventive measures. The EPICOVIDEHA registry <lb/>stands as a vital tool in this ongoing battle, offering <lb/>valuable insights into the ever-changing landscape of <lb/>COVID-19 in hematological malignancy patients. 32 <lb/>However, our study has several limitations. Firstly, <lb/>there is the potential for selection bias due to the use of <lb/>retrospective data from specific institutions. Being an <lb/>observational study, the results may be influenced by <lb/>confounding variables and potential reporting bias <lb/>stemming from self-reported data. Factors that vary with <lb/>time and the validation process could also impact the <lb/>findings, and the study&apos;s design makes it difficult to <lb/>establish causation reliably. Additionally, the absence of <lb/>viral sequencing and serological data for all patients may <lb/>limit a comprehensive understanding of patient risk and <lb/>the natural history of infection. Furthermore, the lack of <lb/>specific denominators due to the scarcity of cases hin-<lb/>ders the ability to provide critical information. Further <lb/>analyses should also provide information with this re-<lb/>gard. Additionally, such analyses would also benefit from <lb/>reporting the days between the different vaccine doses <lb/>and the baseline malignancy diagnosis or the existence <lb/>of previous COVID-19 episodes, as this may impact in <lb/>the evolution of the infectious episode, specially in the <lb/>last semesters. Ultimately, the diverse international and <lb/>multicentric approach adopted in this manuscript may <lb/>have introduced variability in the findings. This variation <lb/>could be attributed to differing timelines in the imple-<lb/>mentation of preventive measures, variations in vaccine <lb/>types, discrepancies in diagnostic test performance, or <lb/>even disparities in the availability of treatments for <lb/>COVID-19. It is inherently challenging to determine the <lb/>Fig. 3: Continued. <lb/>Fig. 3: EPICOVIDEHA 2020-2022 patients: survival probability per diagnosis semester, vaccination status, and COVID-19 treatment. A) <lb/>2020-2022 survival probability per semester. This figure has been replicated with the survival probability ranging from 70% to 100% in <lb/>Supplementary Fig. S8. B) 2020-2022 survival probability per vaccine doses before COVID-19. This figure has been replicated with the survival <lb/>probability ranging from 70% to 100% in Supplementary Fig. S9. C) 2020-2022 survival probability per vaccine doses before COVID-19 and <lb/>COVID-19 treatment, 0 vaccines. AVs, antivirals; MoABs, monoclonal antibodies. * No treatment includes patients that did not need to receive <lb/>treatment mainly due to lack of symptoms. This figure has been replicated with the survival probability ranging from 70% to 100% in <lb/>Supplementary Fig. S10. D) 2020-2022 survival probability per vaccine doses before COVID-19 and COVID-19 treatment, 1-2 vaccines. AVs, <lb/>antivirals; MoABs, monoclonal antibodies. *No treatment includes patients that did not need to receive treatment mainly due to lack of <lb/>symptoms. This figure has been replicated with the survival probability ranging from 70% to 100% in Supplementary Fig. S11. E) 2020-2022 <lb/>survival probability per vaccine doses before COVID-19 and COVID-19 treatment, 3+ vaccines. AVs, antivirals; MoABs, monoclonal antibodies. <lb/>*No treatment includes patients that did not need to receive treatment mainly due to lack of symptoms. This figure has been replicated with <lb/>the survival probability ranging from 70% to 100% in Supplementary Fig. S12. <lb/></body>

			<note place="headnote">Articles <lb/></note>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<page>17 <lb/></page>

            <body>number of SARS-CoV-2-infected patients treated at the <lb/>participating institutions who went undiagnosed during <lb/>this timeframe. However, it is plausible that the figures <lb/>for 2022, particularly in the last six months, are affected <lb/>by individuals with mild infections who may not have <lb/>sought medical attention, and physicians might not have <lb/>actively pursued virologic diagnoses for patients with <lb/>mild symptoms. Consequently, these cases cannot be <lb/>incorporated into the report, and it is imperative to <lb/>recognize this as a limitation. Finally, to enhance the <lb/>accessibility of our findings for our target audience, <lb/>primarily hematologists and infectious diseases medical <lb/>professionals, who may lack advanced statistical profi-<lb/>ciency, we have streamlined our analysis to strike a bal-<lb/>ance between complexity and clarity. As such, we have <lb/>excluded intricate analyses within our multivariable Cox <lb/>regression model, recognizing that not all variables <lb/>maintain proportionality over time or linearity. This <lb/>omission of comprehensive analysis may result in con-<lb/>servative estimations, particularly impacting variables <lb/>such as vaccination status as a protective factor and pa-<lb/>tient stay during the COVID-19 episode as a risk factor. <lb/>In simpler terms, the results from the multivariable Cox <lb/>regression model would require adjustments based on <lb/>the specific duration of exposure. Consequently, the <lb/>hazard ratio for vaccination may decrease over time with <lb/>increased vaccine doses (being the vaccines even more <lb/>protective than what reported here), while it may rise <lb/>with hospital or ICU admission during the COVID-19 <lb/>episode (being these admissions even more risky than <lb/>what reported here). Given these considerations, while <lb/>urging caution in interpreting our findings, we recom-<lb/>mend future analyses to address this limitation. Despite <lb/>these limitations, the study offers valuable insights into <lb/>COVID-19 outcomes in patients with hematological <lb/>malignancies, expanding our knowledge in this field. <lb/>In conclusion, the data from the EPICOVIDEHA <lb/>registry offer a multifaceted view of the COVID-19 <lb/>pandemic for patients with hematological malig-<lb/>nancies. While there have been improvements, the road <lb/>ahead remains challenging. The findings from this <lb/>extensive dataset underscore the critical importance of <lb/>vaccination, prophylactic measures, and vigilant moni-<lb/>toring. As the COVID-19 situation continues to evolve, <lb/>we must persist in learning, adapting, and advocating <lb/>for the well-being of patients with hematological ma-<lb/>lignancies. Through ongoing research and collabora-<lb/>tion, we can navigate the ever-changing COVID-19 <lb/>landscape and provide the best possible care for this <lb/>vulnerable patient population. <lb/></body>

            <div type="annex">Contributors <lb/>JSG, FM, LP and OAC contributed to study design and study supervi-<lb/>sion. JSG did the statistical plan and analysis. JSG and OAC interpreted <lb/>the data and wrote the paper. All the authors recruited, and documented <lb/>participants, critically read, reviewed, and agreed to publish the <lb/>manuscript. <lb/></div>

            <div type="availability">Data sharing statement <lb/>The corresponding author can provide the data supporting the findings <lb/>of this study upon a reasonable request. <lb/></div>

            <div type="annex">Declaration of interests <lb/>JSG has received payment or honoraria for lectures, presentations, <lb/>speakers bureaus, manuscript writing or educational events from <lb/>Gilead, Menarini, and Pfizer; and has participated on a Data Safety <lb/>Monitoring Board or Advisory Board for Pfizer, outside of the submitted <lb/>work. <lb/>FI has received payment or honoraria for lectures, presentations, <lb/>speakers bureaus, manuscript writing or educational events from <lb/>Novartis, AbbVie, Gilead; and has received support for attending <lb/>meetings and/or travel from Novartis, AbbVie, Gilead, Astellas, Pfizer, <lb/>Sanofi, BMS, Alexion, Astra-Zeneca, outside of the submitted work. <lb/>MGdS has received grants or contracts from AstraZeneca, consul-<lb/>ting fees from Roche, Janssen Cilag, Gilead, and Abbvie; payment or <lb/>honoraria for lectures, presentations, speakers bureaus, manuscript <lb/>writing or educational events from Janssen; support for attending <lb/>meetings and/or travel from Abbvie, Gilead, and Takeda; and partici-<lb/>pation on a Data Safety Monitoring Board or Advisory Board for Roche, <lb/>Janssen Cilag, Lilly, Gilead, Takeda, and Abbvie, outside of the sub-<lb/>mitted work. <lb/>ALG has received consulting fees from AstraZeneca; payment or <lb/>honoraria for lectures, presentations, speakers bureaus, manuscript <lb/>writing or educational events from Roche, Janssen, and Abbvie; and <lb/>support for attending from meetings and/or travel from Astrazeneca, <lb/>Janssen, and Beigene, outside of the submitted work. <lb/>CGV has received grants or contracts from Ministerio de Sanidad y <lb/>Consumo, Instituto de Salud Carlos III, payment or honoraria for lec-<lb/>tures, presentations, speakers bureaus, manuscript writing or educa-<lb/>tional events from Gilead Science, MSD, Pfizer, Jannsen, Novartis, <lb/>Basilea, GSK, Shionogi, AbbVie, Advanz Pharma, and a grant support <lb/>from Gilead Science, Pfizer, GSK, MSD and Pharmamar, outside of the <lb/>submitted work. <lb/>MM has received payment or honoraria for lectures, presentations, <lb/>speakers bureaus, manuscript writing or educational events from Pfizer, <lb/>GILEAD, MSD, and ViiV Healthcare; and support for attending meet-<lb/>ings and/or travel from Pfizer, Pharmamar, Tillotts Pharma, outside of <lb/>the submitted work. <lb/>SKG has received grants or contracts from Else Kröner-Fresenius-<lb/>Stiftung iPRIME Scholarship (2021_EKPK.10), UKE, Hamburg, outside <lb/>of the submitted work. <lb/>AV has received consulting fees from MSD and Takeda; Payment or <lb/>honoraria for lectures, presentations, speakers bureaus, manuscript <lb/>writing or educational events from Gilead Pharma; and support for <lb/>attending meetings and/or travel from Tillots, outside of the submitted <lb/>work. <lb/>TFA has received a pre-doctoral grant supported by the Ministerio <lb/>de Sanidad y Consumo, Instituto de Salud Carlos III [RH RH042953], <lb/>CM23/00277, outside of the submitted work. <lb/>OAC has received grants or contracts from BMBF, Cidara, EU-DG <lb/>RTD (101037867), F2G, Gilead, MedPace, MSD, Mundipharma, Octa-<lb/>pharma, Pfizer, Scynexis; consulting fees from Abbvie, AiCuris, Biocon, <lb/>Cidara, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Moderna, <lb/>Molecular Partners, MSG-ERC, Noxxon, Octapharm, Pfizer, PSI, Scy-<lb/>nexis, Seres; payment or honoraria for lectures, presentations, speakers <lb/>bureaus, manuscript writing or educational events from Abbott, Abbvie, <lb/>Al-Jazeera Pharmaceuticals/Hikma, Gilead, Grupo Biotoscana/United <lb/>Medical/Knight, MedScape, MedUpdate, Merck/MSD, Noscendo, <lb/>Pfizer, Shionogi, streamedup!; Payment for expert testimony from <lb/>Cidara; a German patent (&quot;Geschlossene Inkubationssysteme mit ver-<lb/>bessertem Atemwegszugang für Untersuchungsvorrichtungen&quot;, DE 10 <lb/>2021 113 007.7), filed by the University of Cologne and listing Oliver A. <lb/>Cornely as one of three inventors; Participation on a Data Safety <lb/>Monitoring Board or Advisory Board from Boston Strategic Partners, <lb/>Cidara, IQVIA, Janssen, MedPace, PSI, Pulmocide, Shionogi, The <lb/>Prime Meridian Group; Stock or stock options from CoRe Consulting, <lb/></div>

			<note place="headnote">Articles <lb/></note>

			<page>18 <lb/></page>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<div type="annex">EasyRadiology; and Other financial or non-financial interests from <lb/>Wiley, outside of the submitted work. <lb/>JM has received consulting fees from Takeda, F2G, and Mundi-<lb/>pharma; payment or honoraria for lectures, presentations, speakers <lb/>bureaus, manuscript writing or educational events from Takeda, F2G, <lb/>and Mundipharma; and participation on a data safety monitoring board <lb/>or advisory board from Takeda and Mundipharma, outside of the sub-<lb/>mitted work. <lb/>JB has received payment or honoraria for lectures, presentations, <lb/>speakers bureaus, manuscript writing or educational events from <lb/>Janseen, Takeda and Pfizer and support for attending meetings and/or <lb/>travel from Janssen and Pfizer, outside of the submitted work. <lb/>ASO has received payment or honoraria for lectures, presentations, <lb/>speakers bureaus, manuscript writing or educational events from Pfizer, <lb/>Gilead, MSD, and BioMeriuex, outside of the submitted work. <lb/>CDR has received grants or contracts from Asociación Española <lb/>Contra el Cáncer: Code Grant: CLJUN18010DERA (01/10/18-30/11/ <lb/>22), outside of the submitted work. <lb/>NK has received propatient research grant: Third Party Donor <lb/>Registry for personalized antiviral T-Cell immunotherapeutics, no. pp <lb/>20-34; SNSF: Epstein-Barr virus-specific T memory stem cell therapy, <lb/>Projektförderung (Abt. I-III), no. 204944, SNSF: NCCR AntiResist, no. <lb/>180541; consulting fees from MSD Sharp &amp; Dome, Pfizer, Gilead Sci-<lb/>ences, and Takeda; patents planes, issued or pending for corss protective <lb/>epitopes of Aspergillus fumigatus and Candida albicans; participation on a <lb/>data safety mornitoing board or advisory board or Idorsia and Pulmo-<lb/>cide; and Leadership or fiduciary role in other board, society, committee <lb/>or advocacy groups, paid or unpaid for Fungal Infection Network of <lb/>Switzerland (FUNGINOS), outside of the submitted work. <lb/>RDB has been conference speaker to Novartis, Kite/Gilead, Pfizer, <lb/>Abbie, and Incyte; has received travel accommodation from Kite/Gilead; <lb/>and has participated in Scientific advisory board for Novartis, Kite/ <lb/>Gilead, Janssen, and BMS, outside of the submitted work. <lb/>JAHR has received grants or contracts from BMS/Celgene, Janssen, <lb/>Sanofi, and GSK; Consulting fees from Janssen, Roche, Abbvie, Gilead, <lb/>BMS/Celgene, Amgen, Takeda, Rovi, AstraZeneca, Sandoz Novartis, <lb/>Celltrion, EusaPharm, Sanofi, Beigene, and Lilly; and payment or hon-<lb/>oraria for lectures, presentations, speakers bureaus, manuscript writing <lb/>or educational events from Janssen, Roche, Abbvie, Gilead, BMS/Cel-<lb/>gene, Amgen, Takeda, AstraZeneca, Beigene, Lilly, and GSK, outside of <lb/>the submitted work. <lb/>LD has received payment or honoraria for lectures, presentations, <lb/>speakers bureaus, manuscript writing or educational events from Pfizer; <lb/>and support for attending meetings and/or travel from Pfizer, outside of <lb/>the submitted work. <lb/>PK has received grants from German Federal Ministry of Research <lb/>and Education (BMBF) B-FAST (Bundesweites Forschungsnetz Ange-<lb/>wandte Surveillance und Testung) and NAPKON (Nationales Pandemie <lb/>Kohorten Netz, German National Pandemic Cohort Network) of the <lb/>Network University Medicine (NUM) and the State of North Rhine-<lb/>Westphalia; consulting fees from Ambu GmbH, Gilead Sciences, <lb/>Mundipharma Resarch Limited, Noxxon N.V., Pfizer Pharma; payment <lb/>or honoraria for lectures, presentations, speakers bureaus, manuscript <lb/>writing or educational events from Akademie für Infektionsmedizin <lb/>e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., Euro-<lb/>pean Confederation of Medical Mycology, Gilead Sciences, GPR Acad-<lb/>emy Ruesselsheim, HELIOS Kliniken GmbH, Jazz Pharmaceuticals <lb/>Germany GmbH, medupdate GmbH, MedMedia GmbH, MSD Sharp &amp; <lb/>Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica <lb/>SC and University Hospital, LMU Munich; A German patent application <lb/>(&quot;Geschlossene Intubationssysteme mit verbessertem Atemwegszugang <lb/>für Untersuchungsvorrichtungen&quot;, official file number DE 10 <lb/>2021 113 007.7) has been filed by the University of Cologne; Participa-<lb/>tion on a Data Safety Monitoring Board or Advisory Board from Ambu <lb/>GmbH, Gilead Sciences, Pfizer Pharma, Mundipharma Resarch <lb/>Limited, Noxxon N.V.; and Other financial or non-financial interests <lb/>from Elsevier, Wiley, outside of the submitted work. <lb/>PJ has received Payment or honoraria for lectures, presentations, <lb/>speakers bureaus, manuscript writing or educational events from GSK; <lb/>Payment for expert testimony from Takeda; Support for attending <lb/>meetings and/or travel from AstraZeneca, Novartis; and Participation on <lb/>a Data Safety Monitoring Board or Advisory Board Takeda, BMS, outside <lb/>of the submitted work. <lb/>All authors had full access to the data and had final responsibility for <lb/>the decision to submit for publication. <lb/></div>

			<div type="acknowledgement">Acknowledgements <lb/>The authors express their gratitude to all participating institutions for <lb/>their invaluable contributions and unwavering support to the project <lb/>during this challenging pandemic situation. <lb/></div>

			<div type="annex">Appendix A. Supplementary data <lb/>Supplementary data related to this article can be found at https://doi. <lb/>org/10.1016/j.eclinm.2024.102553. <lb/></div>

			<listBibl>References <lb/>1 Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with <lb/>hematologic malignancies and COVID-19: a systematic review and <lb/>meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892. <lb/>2 Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 <lb/>infection in adult patients with hematological malignancies: a Eu-<lb/>ropean Hematology Association Survey (EPICOVIDEHA). <lb/>J Hematol Oncol. 2021;14(1):168. <lb/>3 Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 <lb/>outcomes in patients with cancer. J Clin Oncol. 2020;38(30):3538-<lb/>3546. <lb/>4 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the <lb/>BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27): <lb/>2603-2615. <lb/>5 Sun F, Lin Y, Wang X, Gao Y, Ye S. Paxlovid in patients who are <lb/>immunocompromised and hospitalised with SARS-CoV-2 infec-<lb/>tion. Lancet Infect Dis. 2022;22(9):1279. <lb/>6 RECOVERY collaborative group. Casirivimab and imdevimab in <lb/>patients admitted to hospital with COVID-19 (RECOVERY): a <lb/>randomised, controlled, open-label, platform trial. Lancet. <lb/>2022;399(10325):665-676. <lb/>7 Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough <lb/>COVID-19 in vaccinated patients with hematologic malignancies: <lb/>results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773-<lb/>2787. <lb/>8 Blennow O, Salmanton-García J, Nowak P, et al. Outcome of <lb/>infection with omicron SARS-CoV-2 variant in patients with he-<lb/>matological malignancies: an EPICOVIDEHA survey report. Am J <lb/>Hematol. 2022;97(8):E312-E317. <lb/>9 Perry C, Luttwak E, Balaban R, et al. Efficacy of the BNT162b2 <lb/>mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin <lb/>lymphoma. Blood Adv. 2021;5(16):3053-3061. <lb/>10 Salmanton-García J, Marchesi F, Gomes da Silva M, et al. Nirma-<lb/>trelvir/ritonavir in COVID-19 patients with haematological malig-<lb/>nancies: a report from the EPICOVIDEHA registry. <lb/>eClinicalMedicine. 2023;58:101939. <lb/>11 Salmanton-García J, Marchesi F, Koehler P, et al. Molnupiravir <lb/>compared to nirmatrelvir/ritonavir for COVID-19 in high-risk <lb/>patients with haematological malignancy in Europe. A matched-<lb/>paired analysis from the EPICOVIDEHA registry. Int J Anti-<lb/>microb Agents. 2023;62(4):106952. <lb/>12 Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of <lb/>paxlovid in reducing severe coronavirus disease 2019 and <lb/>mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342-<lb/>e349. <lb/>13 Marchesi F, Salmanton-García J, Buquicchio C, et al. Passive pre-<lb/>exposure immunization by tixagevimab/cilgavimab in patients <lb/>with hematological malignancy and COVID-19: matched-paired <lb/>analysis in the EPICOVIDEHA registry. J Hematol Oncol. <lb/>2023;16(1):32. <lb/>14 Cesaro S, Mikulska M, Hirsch HH, et al. Update of recom-<lb/>mendations for the management of COVID-19 in patients with <lb/>haematological malignancies, haematopoietic cell transplantation <lb/>and CAR T therapy, from the 2022 European Conference on <lb/>Infections in Leukaemia (ECIL 9). Leukemia. 2023;37(9):1933-<lb/>1938. <lb/>15 Davis JA, Granger K, Roubal K, et al. Efficacy of tixagevimab-<lb/>cilgavimab in preventing SARS-CoV-2 for patients with B-cell ma-<lb/>lignancies. Blood. 2023;141(2):200-203. <lb/></listBibl>

			<note place="headnote">Articles <lb/></note>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 <lb/></note>

			<page>19 <lb/></page>

			<listBibl>16 Haidar G, Agha M, Bilderback A, et al. Prospective evaluation of <lb/>coronavirus disease 2019 (COVID-19) vaccine responses across a <lb/>broad spectrum of immunocompromising conditions: the COVID-<lb/>19 vaccination in the immunocompromised study (COVICS). Clin <lb/>Infect Dis. 2022;75(1):e630-e644. <lb/>17 Gardanova Z, Belaia O, Zuevskaya S, Turkadze K, Strielkowski W. <lb/>Lessons for medical and health education learned from the COVID-<lb/>19 pandemic. Healthcare. 2023;11(13):1921. <lb/>18 Giesen N, Busch E, Schalk E, et al. AGIHO guideline on evidence-<lb/>based management of COVID-19 in cancer patients: 2022 update <lb/>on vaccination, pharmacological prophylaxis and therapy in light of <lb/>the omicron variants. Eur J Cancer. 2023;181:102-118. <lb/>19 Busca A, Salmanton-Garcia J, Corradini P, et al. COVID-19 and <lb/>CAR T cells: a report on current challenges and future directions <lb/>from the EPICOVIDEHA survey by EHA-IDWP. Blood Adv. 2022; <lb/>6(7):2427-2433. <lb/>20 Busca A, Salmanton-Garcia J, Marchesi F, et al. Outcome of <lb/>COVID-19 in allogeneic stem cell transplant recipients: results <lb/>from the EPICOVIDEHA registry. Front Immunol. 2023;14: <lb/>1125030. <lb/>21 Cattaneo C, Salmanton-Garcia J, Marchesi F, et al. Simultaneous <lb/>onset of haematological malignancy and COVID: an epicovideha <lb/>survey. Cancers. 2022;14(22):5530. <lb/>22 Criscuolo M, Salmanton-Garcia J, Fracchiolla N, et al. SARS-CoV-2 <lb/>infection in patients with mastocytosis: an EPICOVIDEHA report. <lb/>J Investig Allergol Clin Immunol. 2023;33(3):225-227. <lb/>23 El-Ashwah S, Salmanton-Garcia J, Bilgin YM, et al. The mortality <lb/>of COVID-19 in CML patients from 2020 until 2022: results <lb/>from the EPICOVIDEHA survey. Leuk Lymphoma. 2023;65:199-<lb/>208. <lb/>24 Infante MS, Salmanton-Garcia J, Fernandez-Cruz A, et al. B-cell <lb/>malignancies treated with targeted drugs and SARS-CoV-2 infec-<lb/>tion: a European Hematology Association Survey (EPI-<lb/>COVIDEHA). Front Oncol. 2022;12:992137. <lb/>25 Lamure S, Salmanton-Garcia J, Robin-Marieton E, et al. COVID-19 <lb/>and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Adv. <lb/>2022;6(13):3870-3874. <lb/>26 Marchesi F, Salmanton-Garcia J, Emarah Z, et al. COVID-19 in <lb/>adult acute myeloid leukemia patients: a long-term follow-up study <lb/>from the European Hematology Association survey (EPI-<lb/>COVIDEHA). Haematologica. 2023;108(1):22-33. <lb/>27 Marchetti M, Salmanton-Garcia J, El-Ashwah S, et al. Outcomes of <lb/>SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neo-<lb/>plasms: results from the EPICOVIDEHA registry. Ther Adv Hem-<lb/>atol. 2023;14:20406207231154706. <lb/>28 Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 in <lb/>vaccinated adult patients with hematological malignancies: preli-<lb/>minary results from EPICOVIDEHA. Blood. 2022;139(10):1588-1592. <lb/>29 Rossi G, Salmanton-Garcia J, Cattaneo C, et al. Age, successive <lb/>waves, immunization, and mortality in elderly COVID-19 hema-<lb/>tological patients: EPICOVIDEHA findings. Int J Infect Dis. <lb/>2023;137:98-110. <lb/>30 Salmanton-García J, Busca A, Cornely OA, et al. EPICOVIDEHA: a <lb/>ready to use platform for epidemiological studies in hematological <lb/>patients with COVID-19. Hemasphere. 2021;5(7):e612. <lb/>31 Salmanton-García J, Marchesi F, Glenthøj A, et al. Improved clin-<lb/>ical outcome of COVID-19 in hematologic malignancy patients <lb/>receiving a fourth dose of anti-SARS-CoV-2 vaccine: an EPI-<lb/>COVIDEHA report. Hemasphere. 2022;6(11):e789. <lb/>32 Salmanton-Garcia J, Marchesi F, Itri F, et al. Unveiling the hidden <lb/>burden: from EPICOVIDEHA to EPIFLUEHA, exploring the <lb/>epidemiology of respiratory viral infections in hematological pa-<lb/>tients. Hemasphere. 2023;7(11):e970. <lb/>33 van Doesum JA, Salmanton-Garcia J, Marchesi F, et al. Impact of <lb/>SARS-CoV-2 vaccination and monoclonal antibodies on outcome <lb/>post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. <lb/>Blood Adv. 2023;7(11):2645-2655. <lb/>34 World Health Organization. COVID-19 clinical management. Living <lb/>guidance World Health Organization. 2021. January 15, 2021. WHO/ <lb/>2019-nCoV/clinical/2021.1. <lb/>35 Segura Fábrega A, Pérez Catalán I, Gómez Alfaro I, et al. Associ-<lb/>ation of nirmatrelvir/ritonavir and remdesivir as treatment for <lb/>SARS-CoV-2 infection in immunocompromised patients with he-<lb/>matologic malignancies. Series of four cases. Rev Española Qui-<lb/>mioter. 2023;36(6):655-657. <lb/>36 Spiliopoulou V, Ntanasis-Stathopoulos I, Malandrakis P, et al. Use <lb/>of oral antivirals ritonavir-nirmatrelvir and molnupiravir in patients <lb/>with multiple myeloma is associated with low rates of severe <lb/>COVID-19: a single-center, prospective study. Viruses. <lb/>2023;15(3):704. <lb/>37 Bołkun Ł, Pula B, Kołkowska-Le śniak A, et al. Molnupiravir is <lb/>effective in patients with haematological malignancies. Int J Cancer. <lb/>2023;153(6):1251-1256. <lb/>38 Marziano V, Guzzetta G, Menegale F, et al. Estimating SARS-CoV-<lb/>2 infections and associated changes in COVID-19 severity and fa-<lb/>tality. Influenza Other Respir Viruses. 2023;17(8):e13181. <lb/>39 Simeunovic G, Polega J, Toor S, Andersen NJ. Retrospective anal-<lb/>ysis of vaccinated and unvaccinated COVID-19 patients treated with <lb/>monoclonal antibodies (mAb) and their emergent needs (RAVEN). <lb/>Vaccines (Basel). 2023;11(3):688. <lb/></listBibl>

			<note place="headnote">Articles <lb/></note>

			<page>20 <lb/></page>

			<note place="footnote">www.thelancet.com Vol 71 May, 2024 </note>


	</text>
</tei>
